Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Executive summary Despite substantial progress in reducing the global impact of many non-
communicable diseases, including heart disease and cancer, morbidity and mortality due to …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

Aim This clinical practice guideline for the evaluation and diagnosis of chest pain provides
recommendations and algorithms for clinicians to assess and diagnose chest pain in adult …

Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a
multinational collaborative research study with> 10,000 collaborators around the world. GBD …

Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by
chronic comorbidities including cardiovascular diseases, chronic kidney disease, and …

Background A polypill that includes key medications associated with improved outcomes
(aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as …

Haemodialysis (HD) is the commonest form of kidney replacement therapy in the world,
accounting for approximately 69% of all kidney replacement therapy and 89% of all dialysis …